# Three Month Efficacy/Safety Study With a 3-Month Safety Extension of Brinzolamide 1%/Brimonidine 0.2% vs. Brinzolamide 1% or Brimonidine 0.2%

> **NCT01297920** · PHASE3 · COMPLETED · sponsor: **Alcon Research** · enrollment: 1062 (actual)

## Conditions studied

- Open-Angle Glaucoma
- Ocular Hypertension

## Interventions

- **DRUG:** Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension
- **DRUG:** Brinzolamide ophthalmic suspension, 1%
- **DRUG:** Brimonidine tartrate ophthalmic solution, 0.2%

## Key facts

- **NCT ID:** NCT01297920
- **Lead sponsor:** Alcon Research
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-03
- **Primary completion:** 2012-06
- **Final completion:** 2012-06
- **Target enrollment:** 1062 (ACTUAL)
- **Last updated:** 2013-07-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01297920

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01297920, "Three Month Efficacy/Safety Study With a 3-Month Safety Extension of Brinzolamide 1%/Brimonidine 0.2% vs. Brinzolamide 1% or Brimonidine 0.2%". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01297920. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*